Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
Date:5/2/2013

CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application).  The application includes composition of matter claims on a new class of melanocortin receptor- specific peptides for sexual dysfunction and other indications.

The '238 application is the first patent application to issue covering a novel family of melanocortin-4 receptor agonist peptides.  The melanocortin-4 receptor mediates sexual response, and agonists have been studied for treatment of both erectile dysfunction and female sexual dysfunction.  Palatin's bremelanotide product, a melanocortin-4 receptor agonist peptide drug administered using an autoinjector, has recently completed Phase 2 human studies for female sexual dysfunction, with pivotal Phase 3 clinical studies scheduled to start later this year.

The peptides in the '238 application demonstrated effects on sexual function in animal models.  Palatin is evaluating these peptides as potential follow-on or second generation products for treatment of sexual dysfunction.  The melanocortin-4 receptor also has potential utility in treatment of obesity, metabolic syndrome and other indications.

"As we move into Phase 3 with bremelanotide for female sexual dysfunction, we are pleased to have new peptides with improved profiles suitable for use as second generation products," stated Carl Spana , Ph.D., President and CEO of Palatin.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies To Present At The 25th Annual ROTH Conference
2. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
5. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
6. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
8. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... 25, 2014 SonaCare Medical, a ... (HIFU) devices, recently participated in the American Urology ... 360° .” Key opinion leaders in urology presented ... to small renal masses while attendees had the ... technologies in hands-on labs. Attendees at the Los ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... $15 million in 2008 on target; Potential label ... expansion could further drive sales, ... MTA: CTIC) reported financial results for the quarter,ended June 30, ... $20,000 for the second quarter of 2007 due primarily to ...
... Mass., Aug. 15 ETEX Corporation, an ... launched an innovative,orthobiologic, EquivaBone(TM). EquivaBone(TM) is a ... with new bone during the healing process., ... Brian Ennis, President and CEO of ETEX ...
... The U.S. hospital,marketplace is multifaceted and ... this challenging marketplace, pharmaceutical and biotechnology,sales people ... to effectively represent their brands. Hospital,formulary decisions ... professionals,focused on efficacy and safety but also ...
Cached Biology Technology:Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 2Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 3Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 4Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 5Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 6Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 7ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM) 2U.S. Hospital Sales Opportunities Maximized Through Functional Optimization 2
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... , Aug. 20, 2013 Based on its ... market, Frost & Sullivan presents TATAA Biocenter with ... Customer Value Leadership. TATAA Biocenter offers an end-to-end ... quantitative reverse transcription polymerase chain reaction (qRT-PCR) to ...
... Fla. , Aug. 19, 2013 /PRNewswire-iReach/ -- Jade Holding Group, ... plastic surgery and wellness centers, has just announced that Dr. ... Month for August. (Photo: http://photos.prnewswire.com/prnh/20130819/MN65951 ) ... medical career in 1970 as an undergraduate at the University of ...
... of tiny microorganismshundreds to thousands of species of bacteria ... to a healthy existence. The gastrointestinal (GI) tractand the ... highest diversity of bacterial species. But how do these ... constantly in flux due to foods and fluids moving ...
Cached Biology News:Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 2Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 3Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 4Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 5Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 2Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 3A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4
... media are rigid macroporous hydrophilic media. The ... at moderate pressures, while the macroporous beads ... hydrophilic matrix reduces nonspecific binding. Macro-Prep High ... exchanger with very high flow rates and ...
... collection of phage display libraries, human ... and mouse tissues. All cDNA libraries ... size of cDNA inserts has been ... 1000bp by gel electrophoresis of DNA ...
... is a competitive enzymeimmunoassay (EIA) for the ... rat serum or plasma. Corticosterone is the ... and mice, and in most non-mammalian vertebrates ... mammals produce both corticosterone and cortisol, in ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: